triple negative breast cancer metastasis prognosis

Release time ：Nov-16,2024

The prognosis for patients with metastatic triple-negative breast cancer (TNBC) is often quite poor. This subtype of breast cancer lacks expression of estrogen receptors, progesterone receptors, and HER2, which makes it less responsive to many standard treatment options, resulting in higher recurrence rates and mortality. Once metastasis occurs, patients typically have a shorter survival time.

Specifically, survival rates after TNBC metastasis are influenced by several factors. The location of the metastasis is crucial; for instance, bone metastases may carry a better prognosis than brain metastases. Additionally, the patient's age, overall health status, and the presence of other comorbidities can impact the prognosis. The tumor's biological features, including grade and genetic mutation profiles, also play a role in determining the prognosis. Lastly, the choice of treatment regimen and the patient's response to therapy are significant factors in prognosis determination.

For patients with metastatic TNBC, it is advised to closely monitor disease progression and undergo regular follow-ups. Maintaining a healthy lifestyle, such as a balanced diet and regular exercise, can contribute to better quality of life. During treatment, it is imperative to adhere to the physician's recommendations, complete the prescribed treatment plan without interruption or alteration, and seek medical advice promptly for any discomfort or concerns.